Zunsemetinib

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameZunsemetinib
Drug Alias NameZumsemetinibATI-450CDD-450
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-activated protein kinase 2 inhibitors
TargetsMAP kinase-activated protein kinase 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HR-positive breast cancerCryopyrin-Associated Periodic Syndromes +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesConfluence Life Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineAclaris Therapeutics IncThe University Of Kansas Medical Center
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)HR-positive breast cancerArthritis, Rheumatoid +[7] 
Inactive IndicationsCryopyrin-Associated Periodic SyndromesArthritis, Psoriatic

Other Information

ATC CodeN/A
Related LinksN/A